Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

The National Institute of Allergy and Infectious Diseases (NIAID) has issued a presolicitation notice (BAA 75N93026R00008) for the renewal of the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) program. This initiative, jointly supported by NIAID's Divisions of AIDS, Allergy Immunology and Transplantation, and Microbiology and Infectious Diseases, aims to accelerate TB vaccine development. The program will focus on characterizing tissue-specific and systemic immune responses to Mtb infection, advancing tools and resources for vaccine development, and understanding the impact of HIV/SIV on Mtb immunity. Research will involve human samples, clinical studies, animal models, and computational data integration. Investigators may also use new approach methods like organoids. The program will support the identification of protective antigens and immune epitopes, translation of knowledge to advance vaccine approaches, and refinement of animal models. It is anticipated that two to three cost-reimbursement contracts, each potentially up to $5 million annually for five years, will be awarded, with performance beginning around September 1, 2027. A portion of each contractor's budget ($300,000/year from years two to five) will be set aside for cross-contract collaborative studies. Proposals will be submitted electronically via the NIAID eCPS website, with the BAA available on SAM.gov around June 2, 2026.